Goldman Sachs maintained a Neutral rating on Gilead Sciences (NASDAQ: GILD) and lowered its price target to $85.00 (from $96.00) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE